Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis

Area of Science:

• Pulmonary Medicine
• Hepatology
• Cardiovascular Medicine

Background:

• Fatty liver disease shares mechanisms with Chronic Obstructive Pulmonary Disease (COPD), including hypoxia, inflammation, and oxidative stress.
• The relationship between COPD, hepatic steatosis, and comorbidities is not well understood.
• Liver density on CT scans non-invasively assesses hepatic steatosis.

Purpose of the Study:

• To investigate the prevalence of hepatic steatosis in COPD patients.
• To determine if hepatic steatosis is associated with comorbidities in COPD.
• To explore the association between liver density and cardiovascular comorbidities in COPD.

Main Methods:

• Utilized the ECLIPSE cohort with 1554 COPD patients and 387 controls.
• Analyzed non-enhanced chest CT scans to measure liver density at T12-L1.
• Assessed severe steatosis using a liver density threshold of <40 Hounsfield Units (HU).

Main Results:

• No significant difference in severe steatosis prevalence between COPD patients (4.7%) and controls (5.2%).
• In COPD patients, lower liver density quartile was linked to higher odds of coronary artery disease (ORa=1.59) and stroke (ORa=2.20) after adjustment.
• Liver density distribution was similar between COPD and control groups.

Conclusions:

• Low liver density is a predictor of cardiovascular comorbidities in the COPD population.
• Despite shared pathways, severe hepatic steatosis prevalence is similar in COPD and controls.
• Liver density may serve as a valuable non-invasive marker for cardiovascular risk in COPD patients.